+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Drugs Market Research Reports

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Liposomal Doxorubicin Market Report and Forecast 2024-2032 - Product Thumbnail Image

Liposomal Doxorubicin Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 200 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis Report - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
Doxorubicin Market 2024-2028 - Product Thumbnail Image

Doxorubicin Market 2024-2028

  • Report
  • August 2024
  • 163 Pages
  • Global
From
Gemcitabine Hydrochloride Market 2024-2028 - Product Thumbnail Image

Gemcitabine Hydrochloride Market 2024-2028

  • Report
  • July 2024
  • 132 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments. In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more